Eisai Suing FDA Over Shortened NCE Exclusivity

Generic Line
A A
New Jersey-based Eisai is suing the FDA over the exclusivity clock assigned to two of its products, claiming the government arbitrarily shortened its five-year exclusivity period from generics competition.

To View This Article:

Login

Subscribe To Generic Line

Buy This Article Now

Add this article to your cart for $40.00